Sponsored Content
- Sponsored Content
- Upstream Processing
A Breakthrough AAV Enhancer to Improve Titers and Reduce Production Costs with Any Serotype, Suspension HEK Cell Type, and Transfection Reagent
BPI Contributor
October 19, 2023
20 Min View
Date: Oct 19, 2023
Duration: 20 Min
Already have an account?
Sponsored by Mirus Bio
This webcast features: Leisha Kopp, Senior Field Applications Scientist, Mirus Bio.
With the exponential increase in clinical trials examining recombinant adeno-associated virus (AAV) for gene therapies, significant upstream manufacturing improvements are needed.
In this webinar, learn strategies to increase viral yields and reduce production costs by incorporating lipid polymer nanocomplexes (LPNCs) and novel enhancers into suspension HEK-based transient transfection platforms.
Review key parameters considered during enhancer development as well as techniques to ensure scalability and seamless adoption from bench to large-scale to AAV manufacturing in a GMP environment.
Key takeaways:
Increased AAV production is achievable regardless of transfection reagent with a novel enhancer.
Multiple serotypes, including AAV2, AAV5, AAV8, and AAV9, benefit from inclusion of the enhancer in any suspension, HEK-based workflow.
Straight forward transfection and enhancer protocols coupled with dedicated scientific support will streamline development timelines.
Higher AAV titers with reduced DNA requirements lead to lower costs per dose.
Just fill out the form below to watch the recorded webcast now.
About the Author
You May Also Like
Sponsored Content
Jun 5 - Jun 6, 2024
Jun 5 - Jun 6, 2024
Exploit Advances in Exosomes to Improve Efficiencies in Drug Delivery: Connect with senior-level executives and scientists who will share new data and novel case studies on advancing EV products through clinical stage towards commercialization
Learn More
